human | Q5 |
P1280 | CONOR.SI ID | 70615907 |
P691 | NL CR AUT ID | jo20000080529 |
P496 | ORCID iD | 0000-0002-0851-0713 |
P3368 | Prabook ID | 415153 |
P3829 | Publons author ID | 2119530 |
P1053 | ResearcherID | G-6094-2017 |
P1153 | Scopus author ID | 55941728700 |
P214 | VIAF ID | 84117517 |
P1343 | described by source | Medvik | Q99413897 |
P108 | employer | Charles University | Q31519 |
Revmatologický ústav | Q30281927 | ||
P734 | family name | Vencovský | Q51914367 |
Vencovský | Q51914367 | ||
Vencovský | Q51914367 | ||
P735 | given name | Jiří | Q168563 |
Jiří | Q168563 | ||
P1412 | languages spoken, written or signed | Czech | Q9056 |
P106 | occupation | researcher | Q1650915 |
immunologist | Q12119633 | ||
rheumatologist | Q5997943 | ||
P21 | sex or gender | male | Q6581097 |
Q57752711 | Q57752711 |
Q57752738 | Q57752738 |
Q121914761 | Dermatomyositis a polymyositis |
Q122006850 | Farmakoterapie revmatických onemocnění |
Q122029420 | Revmatologie |
Q57752724 | 119th ENMC international workshop: Trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10–12 October 2003, Naarden, The Netherlands |
Q56506042 | 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative |
Q34130671 | 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative |
Q58490673 | 2016 ACR-EULAR adult dermatomyositis and polymyositis and juvenile dermatomyositis response criteria-methodological aspects |
Q46815762 | 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri |
Q38849148 | 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology |
Q47924181 | 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Juvenile Dermatomyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology |
Q38849144 | 2016 American College of Rheumatology/European League Against Rheumatism criteria for minimal, moderate, and major clinical response in adult dermatomyositis and polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatri |
Q47653276 | 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups |
Q47699498 | 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. |
Q35554739 | A multicentre, randomised, double blind, placebo controlled phase II study of subcutaneous interferon beta-1a in the treatment of patients with active rheumatoid arthritis. |
Q37604518 | A phase III randomised, double-blind, parallel-group study comparing SB4 with etanercept reference product in patients with active rheumatoid arthritis despite methotrexate therapy |
Q40327635 | A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis |
Q51060022 | A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study. |
Q57752360 | A1.48 Enhanced expression of CD11c on non-classical CD16+peripheral blood monocytes in early rheumatoid arthritis |
Q57752369 | A3.29 Micro-RNA molecules are clearly involved in pathogenesis of idiopathic inflammatory myopathy |
Q57752371 | A3.30 Plasma level of HSP70 protein is increased in czech patients with idiopathic inflammatory myopathy |
Q57752332 | AB0009 Association of MHC Haplotypes with Idiopathic Inflammatory Myopathy in Cohort of Czech Patients |
Q57752346 | AB0163 Comprehensive Analysis of Circulating Mirnas in Patients with Axial Spondyloarthritis |
Q47674978 | Abatacept in the treatment of adult dermatomyositis and polymyositis: a randomised, phase IIb treatment delayed-start trial |
Q54381969 | Acute cricopharyngeal obstruction in dermatomyositis. |
Q57752526 | Adipokine profile is modulated in subcutaneous adipose tissue by TNF inhibitors in patients with rheumatoid arthritis |
Q57752460 | Adiponectin relation to skin changes and dyslipidemia in systemic sclerosis |
Q57752651 | Advanced glycation end-product pentosidine is not a relevant marker of disease activity in patients with rheumatoid arthritis |
Q38834515 | Anti-HMGCR antibodies as a biomarker for immune-mediated necrotizing myopathies: A history of statins and experience from a large international multi-center study |
Q38021653 | Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature |
Q57752454 | Anti-Ro52 epitope mapping in inflammatory myopathies |
Q43498070 | Anti-TNF therapy of ankylosing spondylitis in clinical practice. Results from the Czech national registry ATTRA. |
Q38208567 | Arthritis in idiopathic inflammatory myopathy: clinical features and autoantibody associations |
Q34237586 | Association of circulating miR-223 and miR-16 with disease activity in patients with early rheumatoid arthritis. |
Q41824468 | Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. |
Q57536946 | Autoantibody Specificities and Type I Interferon Pathway Activation in Idiopathic Inflammatory Myopathies |
Q57752590 | CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis |
Q38818188 | Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis |
Q48480707 | Certolizumab pegol plus MTX administered every 4 weeks is effective in patients with RA who are partial responders to MTX. |
Q36045392 | Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients |
Q104613975 | Chemokine and Cytokine Profiles in Patients with Hand Osteoarthritis |
Q58614815 | Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study |
Q41257255 | Clinical associations of IgG antibodies to the ribonucleoprotein p67 polypeptide in patients with systemic lupus erythematosus |
Q37934396 | Clinical trials roundup in idiopathic inflammatory myopathies. |
Q57752845 | Clinical-morphological correlation of polymyositis and dermatomyositis |
Q52816251 | Confirmation on the immunogenicity assay used in the SB4 phase III study: response to the comments by Meacci et al. |
Q57752274 | Corrigendum to “CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis” [Clin. Immunol. 136 (2010) 139–147] |
Q57752356 | Decrease in serum interleukin-21 levels is associated with disease activity improvement in patients with recent-onset rheumatoid arthritis |
Q30839061 | Decreased circulating visfatin is associated with improved disease activity in early rheumatoid arthritis: data from the PERAC cohort |
Q35617658 | Decreases in serum levels of S100A8/9 (calprotectin) correlate with improvements in total swollen joint count in patients with recent-onset rheumatoid arthritis. |
Q52893591 | Delays in assessment of patients with rheumatoid arthritis: variations across Europe. |
Q42098903 | Dense genotyping of immune-related loci in idiopathic inflammatory myopathies confirms HLA alleles as the strongest genetic risk factor and suggests different genetic background for major clinical subgroups |
Q36335887 | Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. |
Q52814958 | Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo. |
Q36424500 | Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases |
Q57752304 | Dr. Vencovsky, et al reply |
Q57245349 | EULAR/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report |
Q54145043 | Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. |
Q37172815 | Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study |
Q37172820 | Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial |
Q57752593 | Elevated prolactin levels in patients with rheumatoid arthritis: association with disease activity and structural damage |
Q57752656 | Endogenous HLA–DR–restricted presentation of the cartilage antigens human cartilage gp-39 and melanoma inhibitory activity in the inflamed rheumatoid joint |
Q37939700 | European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies |
Q36205767 | Expression and Regulation of PIWIL-Proteins and PIWI-Interacting RNAs in Rheumatoid Arthritis. |
Q34528042 | Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies |
Q57752335 | FRI0520 Association Study of the BAFF Genetic Variations in Two Independent Cohorts with Idiopathic Inflammatory Myopathies |
Q92354292 | Focused HLA analysis in Caucasians with myositis identifies significant associations with autoantibody subgroups |
Q57752597 | Genetic variation in promoter sequence of B cell-activating factor gene is associated with increased risk of myositis development |
Q34490287 | Genome-wide association study identifies HLA 8.1 ancestral haplotype alleles as major genetic risk factors for myositis phenotypes. |
Q37601815 | Genome-wide association study of dermatomyositis reveals genetic overlap with other autoimmune disorders |
Q35752908 | Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies. |
Q57752812 | HETEROGENEITY OF DISEASE PHENOTYPE IN MONOZYGOTIC TWINS CONCORDANT FOR RHEUMATOID ARTHRITIS |
Q57752790 | Heterogenous nuclear RNP C1 and C2 core proteins are targets for an autoantibody found in the serum of a patient with systemic sclerosis and psoriatic arthritis |
Q30876263 | High levels of metastasis-inducing S100A4 protein and treatment outcome in early rheumatoid arthritis: data from the PERAC cohort |
Q57752758 | Higher frequency of allele 2 of the interleukin-1 receptor antagonist gene in patients with juvenile idiopathic arthritis |
Q57752480 | IFN signature is associated with autoantibody profiles in patients with myositis |
Q57752786 | IL-10 Gene Promoter Polymorphisms in Rheumatoid Arthritis: SHORT REPORT |
Q57752602 | Immune cell-derived microparticles in polymyositis/dermatomyositis |
Q39021882 | Immune-Array Analysis in Sporadic Inclusion Body Myositis Reveals HLA-DRB1 Amino Acid Heterogeneity Across the Myositis Spectrum |
Q57752797 | Immunoglobulin Variable Region (IgV) Gene Expression in Rheumatoid Factors from Monozygotic Twins with Rheumatoid Arthritis |
Q57752524 | Immunolocalization of protein-bound 3-nitrotyrosine in inflammatory myopathies |
Q50758762 | Immunological investigation in children with juvenile chronic arthritis. |
Q43204037 | Increased serum concentration of immune cell derived microparticles in polymyositis/dermatomyositis |
Q46483118 | Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. |
Q57806415 | Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients |
Q40799107 | Increasing incidence of immune-mediated necrotizing myopathy: single-centre experience. |
Q51730918 | Increasing the infliximab dose in rheumatoid arthritis patients: a randomised, double blind study failed to confirm its efficacy. |
Q42706490 | Inflammatory myopathy associated with statins: report of three cases |
Q36020198 | Interaction of HLA-DRB1*03 and smoking for the development of anti-Jo-1 antibodies in adult idiopathic inflammatory myopathies: a European-wide case study |
Q35882730 | Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid Arthritis. |
Q38702140 | Interleukin-20 is triggered by TLR ligands and associates with disease activity in patients with rheumatoid arthritis. |
Q57752293 | Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early disease |
Q36084879 | International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis |
Q39138840 | International collaboration including patients is essential to develop new therapies for patients with myositis |
Q35179618 | International consensus outcome measures for patients with idiopathic inflammatory myopathies. Development and initial validation of myositis activity and damage indices in patients with adult onset disease. |
Q39745186 | Interrater reliability and aspects of validity of the myositis damage index |
Q47095910 | Long-term efficacy and safety in patients with rheumatoid arthritis continuing on SB4 or switching from reference etanercept to SB4. |
Q57752499 | Low circulating Dickkopf-1 and its link with severity of spinal involvement in diffuse idiopathic skeletal hyperostosis |
Q38644438 | MRI scoring methods used in evaluation of muscle involvement in patients with idiopathic inflammatory myopathies |
Q57752609 | Metastasis-Promoting protein S100A4 (MTS1) upregulates production of proinflammatory cytokines via TLR-4 |
Q44918219 | Metastasis-inducing S100A4 protein is associated with the disease activity of rheumatoid arthritis. |
Q57752504 | Metastasis-inducing S100A4 protein is associated with treatment response in patients with recent-onset rheumatoid arthritis |
Q36960767 | MicroRNA-125b: association with disease activity and the treatment response of patients with early rheumatoid arthritis |
Q57752546 | Modulation of subcutaneous adipose tissue adipokines by TNF- blockade therapy in patients with inflammatory arthritides |
Q50983253 | Molecular markers of systemic autoimmune disorders: the expression of MHC-located HSP70 genes is significantly associated with autoimmunity development. |
Q57752818 | Monozygotic Rheumatoid Arthritis Twin Pairs Express Similar Levels of Conserved Immunoglobulin V Gene in Polyclonal Rheumatoid Factors Irrespective of Disease Status |
Q57752613 | Myositis associated autoantibodies detected using a novel recombinant protein blotting: clinical associations |
Q45233460 | New findings on the pathogenesis of rheumatoid arthritis |
Q57752510 | No effect of physiotherapy on the serum levels of adipocytokines in patients with ankylosing spondylitis |
Q57752516 | Novel adipokine fibroblast growth factor 21 is increased in rheumatoid arthritis |
Q57752365 | OP0235 Genetic Risk Factors in Idiopathic Inflammatory Myopathies Are Shared with Other Autoimmune Disorders in European Populations |
Q57752319 | OP0289 A Prospective, Randomized, Open-Label, Assessor-Blind, Multicenter Study of Efficacy and Safety of Combined Treatment of Methotrexate + Glucocorticoids versus Glucocorticoids Alone in Patients with Polymyositis and Dermatomyositis (Prometheu |
Q57752299 | OSKIRA-4: a phase IIb randomised, placebo-controlled study of the efficacy and safety of fostamatinib monotherapy |
Q42353372 | Opportunities and challenges in rheumatology research in Central Europe |
Q36041246 | Pentosidine, an advanced glycation end-product, may reflect clinical and morphological features of hand osteoarthritis |
Q36588160 | Physiological evidence for diversification of IFNα- and IFNβ-mediated response programs in different autoimmune diseases |
Q57752615 | Polymorphism of the extrapituitary prolactin promoter and systemic sclerosis |
Q57752552 | Potential role of S100A4 in an immune response of rheumatoid arthritis |
Q42956746 | Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate |
Q44147825 | Pregnancy outcome in idiopathic inflammatory myopathy patients in a multicenter study |
Q40636094 | Primary Sjögren's syndrome in children and adolescents: proposal for diagnostic criteria. |
Q57752308 | Pro-inflammatory effects of interleukin-35 in rheumatoid arthritis |
Q56957893 | Proceedings of the 23rd Paediatric Rheumatology European Society Congress: part one |
Q35962863 | Progranulin Is Associated with Disease Activity in Patients with Rheumatoid Arthritis |
Q34440026 | Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies |
Q45208119 | Quantiferon TB Gold and tuberculin skin tests for the detection of latent tuberculosis infection in patients treated with tumour necrosis factor alpha blocking agents |
Q57752665 | Quantiferon-TB Gold test in screening for latent tuberculosis before and during antitumour necrosis factor treatment |
Q57752823 | RHEUMATOID FACTORS AND GERMLINE GENES IN RHEUMATOID ARTHRITIS: EVIDENCE OF AN INTRINSIC B-LYMPHOCYTE DEFECT? |
Q57752669 | Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment |
Q46663336 | Recommendations of Czech Rheumatological Society for the treatment of rheumatoid arthritis. Efficacy and treatment strategies |
Q41497288 | Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study. |
Q57752642 | Reliability and validity of the myositis disease activity assessment tool |
Q36245955 | Resistin in idiopathic inflammatory myopathies |
Q48091996 | Response to: 'Antisynthetase syndrome or what else? Different perspectives indicate the need for new classification criteria' by Cavagna et al. |
Q52816457 | Response to: 'Comparing the immunogenicity of the etanercept biosimilar SB4 with the innovator etanercept: another consideration' by Marshall et al. |
Q52815225 | Response to: 'Lower anti-drug antibodies with etanercept biosimilar: Can Ctrough explain the differences' by Shah. |
Q52817973 | Response to: 'Reporting of potential immunogenicity with biologic drugs: clarity and accuracy required' by Moots et al. |
Q48457754 | Rheumatoid arthritis: the goal rather than the health-care provider is key. |
Q57752324 | SAT0349 A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective, but Substantially Less Costly than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Matched Observational Study: Table 1 |
Q57752376 | SAT0565 The Expression and Regulation of the Argonaute Protein Family Member PIWIL4 in RA |
Q34061733 | Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus |
Q36188496 | Serum Calprotectin Discriminates Subclinical Disease Activity from Ultrasound-Defined Remission in Patients with Rheumatoid Arthritis in Clinical Remission |
Q36067062 | Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis. |
Q90575845 | Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis |
Q57752559 | Serum levels of IFN- do not correlate with disease activity in patients with dermatomyositis/polymyositis |
Q57752562 | Serum levels of interferon do not correlate with disease activity in patients with dermatomyositis/polymyositis |
Q36321563 | Serum tenascin-C discriminates patients with active SLE from inactive patients and healthy controls and predicts the need to escalate immunosuppressive therapy: a cohort study |
Q91532373 | Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study |
Q91314854 | Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry |
Q41500940 | Somatic mutation and CDR3 length of immunoglobulin lambda variable region genes in the synovium of patients with rheumatoid arthritis. |
Q48248837 | Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis |
Q57752350 | THU0528 Decrease in Circulating Visfatin Levels is Associated with Disease Activity Improvement in Early Rheumatoid Arthritis |
Q26765038 | The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation |
Q38601741 | The EuroMyositis registry: an international collaborative tool to facilitate myositis research. |
Q54305524 | The effects of the spleen tyrosine kinase inhibitor fostamatinib on ambulatory blood pressure in patients with active rheumatoid arthritis: results of the OSKIRA-ABPM (ambulatory blood pressure monitoring) randomized trial. |
Q45011283 | The expression of cyclooxygenase-1, cyclooxygenase-2 and 5-lipoxygenase in inflammatory muscle tissue of patients with polymyositis and dermatomyositis. |
Q41862536 | The expression profile of miR-23b is not altered in peripheral blood mononuclear cells of patients with idiopathic inflammatory myopathies |
Q57752566 | The expression regulation of the HSPA1B gene in patients with myositis is not dependent on the presence of HLA-DRB1*03 risk allele |
Q36183786 | The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region |
Q44832774 | The level of fatty acid-binding protein 4, a novel adipokine, is increased in rheumatoid arthritis and correlates with serum cholesterol levels. |
Q57752573 | The level of serum visfatin (PBEF) is associated with total number of B cells in patients with rheumatoid arthritis and decreases following B cell depletion therapy |
Q57752577 | The metastasis promoting protein S100A4 is increased in idiopathic inflammatory myopathies |
Q34560305 | The metastasis promoting protein S100A4 levels associate with disease activity rather than cancer development in patients with idiopathic inflammatory myopathies |
Q57752382 | The metastasis-associated protein S100A4 promotes the inflammatory response of mononuclear cells via the TLR4 signalling pathway in rheumatoid arthritis |
Q57752677 | The role of MRI in the assessment of polymyositis and dermatomyositis |
Q38099557 | The role of resistin in inflammatory myopathies. |
Q46198003 | The significance of antibodies to cyclic citrullinated peptide, antikeratin antibodies, anti-perinuclear factor, rheumatoid factor isotypes and HLA shared epitope in prediction of erosive disease in early rheumatoid arthritis patients. |
Q57752391 | The two mRNA transcription variants of the B-cell activating factor are differentially expressed, but in a stable ratio |
Q57752735 | Therapeutic strategies in polymyositis and dermatomyositis |
Q38246832 | Therapy of myositis: biological and physical |
Q37763782 | Treatment-resistant inflammatory myopathy |
Q57752753 | Tumour necrosis factor α G→A −238 and G→A −308 polymorphisms in juvenile idiopathic arthritis |
Q45141851 | Use of pulsed steroid therapy in active rheumatoid arthritis |
Q57752623 | Vaspin and omentin: new adipokines differentially regulated at the site of inflammation in rheumatoid arthritis |
Q57752703 | [How can the autoantibody detection help in the diagnostics and evaluation of autoimmune rheumatic diseases?] |
Q53758852 | [Immune mediated necrotizing myopathy associated with statin treatment]. |
Q57752803 | [Practical results of monitoring pregnancy in women with systemic lupus erythematosus] |
Q57752808 | [Rheumatoid pericarditis: correlation with immunologic parameters] |
Q57752682 | [Rheumatologic manifestations in diabetes] |
Search more.